Biomarkers and venous thromboembolism

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 3, 2009, Pages 332-336

  Pabinger, Ingrid ^a   Ay, Cihan ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Biomarker; D dimer; P selectin; Recurrence; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; D DIMER; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PADGEM PROTEIN; THROMBIN; TUMOR NECROSIS FACTOR; AUTACOID; BIOLOGICAL MARKER; CYTOKINE; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ARTICLE; CARDIOVASCULAR RISK; DISEASE MARKER; DRUG WITHDRAWAL; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; RECURRENT DISEASE; VENOUS THROMBOEMBOLISM; BLOOD; DRUG ADMINISTRATION; METABOLISM; PREDICTION AND FORECASTING; REVIEW; TREATMENT OUTCOME;

ANTICOAGULANTS; BIOLOGICAL MARKERS; CYTOKINES; DRUG ADMINISTRATION SCHEDULE; FACTOR VIII; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; INFLAMMATION MEDIATORS; P-SELECTIN; PREDICTIVE VALUE OF TESTS; RECURRENCE; THROMBIN; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 61549101213     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.182188     Document Type: Article

References (61)

1. Heit JA. The epidemiology of venous thromboembolism in the community. Arteriosder Thromb Vasc Biol. 2008;28:370-372.
2. Schulman S, Lindmarker P, Holmstrom M, Larfars G, Carlsson A, Nicol P, Svensson E, Ljungberg B, Viering S, Nordlander S, Leijd B, Jahed K, Hjorth M, Linder O, Beckman M. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost. 2006;4:734-742.
3. Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, Kovacs G, Mitchell M, Lewandowski B, Kovacs MJ. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl JMed. 2003;349:1227-1235.
4. Righini M, Perrier A, De Moerloose P, Bounameaux H. D-Dimer for venous thromboembolism diagnosis: 20 years later. J Thromb Haemost. 2008;6:1059-1071.
5. Di Nisio M, Squizzato A, Rutjes AW, Buller HR, Zwinderman AH, Bossuyt PM. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb Haemost. 2007;5: 296-304.
6. Andreescu AC, Cushman M, Rosendaal FR. D-dimer as a risk factor for deep vein thrombosis: the Leiden Thrombophilia Study. Thromb Haemost. 2002;87:47-51.
7. Cushman M, Folsom AR, Wang L, Aleksic N, Rosamond WD, Tracy RP, Heckbert SR. Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood. 2003;101:1243-1248.
8. Verhovsek M, Douketis JD, Yi Q, Shrivastava S, Tait RC, Baglin T, Poli D, Lim W Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med. 2008;149:481-490, W494.
9. Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost. 2002;87:7-12.
10. Eichinger S, Minar E, Bialonczyk C, Hirschl M, Quehenberger P, Schneider B, Weltermann A, Wagner O, Kyrle PA. D-dimer levels and risk of recurrent venous thromboembolism. JAMA. 2003;290:1071-1074.
11. Palareti G, Legnani C, Cosmi B, Valdre L, Lunghi B, Beraardi F, Coccheri S. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation. 2003;108:313-318.
12. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Lensing AW, Tripodi A. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006;355:1780-1789.
13. McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost. 2001;86: 746-756.
14. Cambien B, Wagner DD. A new role in hemostasis for the adhesion receptor P-selectin. Trends Mol Med. 2004;10:179-186.
15. Furie B, Furie BC. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med. 2004;10:171-178.
16. Wakefield TW, Myers DD, Henke PK. Mechanisms of venous thrombosis and resolution. Arteriosder Thromb Vasc Biol. 2008;28: 387-391.
17. Frenette PS, Denis CV, Weiss L, Jurk K, Subbarao S, Kehrel B, Hartwig JH, Vestweber D, Wagner DD. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med. 2000;191:1413-1422.
18. Polgar J, Matuskova J, Wagner DD. The P-selectin, tissue factor, coagulation triad. J Thromb Haemost. 2005;3:1590-1596.
19. Vandendries ER, Furie BC, Furie B. Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost. 2004;92:459-466.
20. Hrachovinova I, Cambien B, Hafezi-Moghadam A, Kappelmayer J, Camphausen RT, Widom A, Xia L, Kazazian HH Jr, Schaub RG, McEver RP, Wagner DD. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med. 2003;9:1020-1025.
21. Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD. Procoagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci U S A. 2000;97:13835-13840.
22. Myers DD, Hawley AE, Farris DM, Wrobleski SK, Thanaporn P, Schaub RG, Wagner DD, Kumar A, Wakefield TW. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg. 2003;38:1075-1089.
23. Celi A, Pellegrini G, Lorenzet R, De Blasi A, Ready N, Furie BC, Furie B. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci U S A. 1994;91:8767-8771.
24. del Conde I, Nabi F, Tonda R, Thiagarajan P, Lopez JA, Kleiman NS. Effect of P-selectin on phosphatidylserine exposure and surface-dependent thrombin generation on monocytes. Arterioscler Thromb Vasc Biol. 2005;25:1065-1070.
25. Smith A, Quarmby JW, Collins M, Lockhart SM, Burnand KG. Changes in the levels of soluble adhesion molecules and coagulation factors in patients with deep vein thrombosis. Thromb Haemost. 1999;82: 1593-1599.
26. Rectenwald JE, Myers DD Jr, Hawley AE, Longo C, Henke PK, Guire KE, Schmaier AH, Wakefield TW. D-dimer, P-selectin, and microparticles: novel markers to predict deep venous thrombosis. A pilot study. Thromb Haemost. 2005;94:1312-1317.
27. Blann AD, Noteboom WM, Rosendaal FR. Increased soluble P-selectin levels following deep venous thrombosis: cause or effect? Br J Haematol. 2000;108:191-193.
28. Ay C, Jungbauer LV, Sailer T, Tengler T, Koder S, Kaider A, Panzer S, Quehenberger P, Pabinger I, Mannhalter C. High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. Clin Chem. 2007;53:1235-1243.
29. Kyrie PA, Hron G, Eichinger S, Wagner O. Circulating P-selectin and the risk of recurrent venous thromboembolism. Thromb Haemost. 2007;97: 880-883.
30. Bugert P, Pabinger I, Stamer K, Vormittag R, Skeate RC, Wahi MM, Panzer S. The risk for thromboembolic disease in lupus anticoagulant patients due to pathways involving P-selectin and CD 154. Thromb Haemost. 2007;97:573-580.
31. Ay C, Jungbauer LV, Kaider A, Koder S, Panzer S, Pabinger I, Mannhalter C. P-selectin gene haplotypes modulate soluble P-selectin concentrations and contribute to the risk of venous thromboembolism. Thromb Haemost. 2008;99:899-904.
32. Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S, Kornek G, Marosi C, Wagner O, Zielinski C, Pabinger I. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2008;112:2703-2708.
33. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
34. Prandoni P. Links between arterial and venous disease. J Intern Med. 2007;262:341-350.
35. Lowe GD. Arterial disease and venous thrombosis: are they related, and if so, what should we do about it? J Thromb Haemost. 2006;4:1882-1885.
36. Ay C, Tengler T, Vormittag R, Simanek R, Dorda W, Vukovich T, Pabinger I. Venous thromboembolism-a manifestation of the metabolic syndrome. Haematologica. 2007;92:374-380.
37. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993;82:513-520.
38. Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost. 2005;94:362-365.
39. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM, Rosendaal FR. Increased levels of factor VIII. and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost. 1999;81:680-683.
40. van Aken BE, den Heijer M, Bos GM, van Deventer SJ, Reitsma PH. Recurrent venous thrombosis and markers of inflammation. Thromb Haemost. 2000;83:536-539.
41. Reitsma PH, Rosendaal FR. Activation of innate immunity in patients with venous thrombosis: the Leiden Thrambophilia Study. J Thromb Haemost. 2004;2:619-622.
42. Vormittag R, Vukovich T, Schonauer V, Lehr S, Minar E, Bialonczyk C, Hirschl M, Pabinger I. Basal high-sensitivity-C-reactive protein levels in patients with spontaneous venous thromboembolism. Thromb Haemost. 2005;93:488-493.
43. Vormittag R, Hsieh K, Kaider A, Minar E, Bialonczyk C, Hirschl M, Mannhalter C, Pabinger I. Interleukin-6 and interleukin-6 promoter polymorphism (-174) G>C in patients with spontaneous venous thromboembolism. Thromb Haemost. 2006;95:802-806.
44. Vormittag R, Funk M, Mannhalter C, Schonauer V, Vukovich T, Minar E, Bialonczyk C, Hirschl M, Pabinger I. C-reactive protein 3′ UTR + 1444>T polymorphism in patients with spontaneous venous thromboembolism. Atherosclerosis. 2006;188:406-411.
45. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, Folsom AR. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med. 2002;113:636-642.
46. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345:152-155.
47. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S. High plasma levels of factor Vil! and the risk of recurrent venous thromboembolism. N Engl J Med. 2000;343:457-462.
48. Cosrni B, Legnani C, Cini M, Favaretto E, Palareti G. D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. Thromb Res. 2008;122:610-617.
49. Legnani C, Cosmi B, Cini M, Frascaro M, Guazzaloca G, Palareti G. High plasma levels of factor VIII and risk of recurrence of venous thromboembolism. Br J Haematol. 2004;124:504-510.
50. Bischer L, Gartner V, Schulman S, Kyrle PA, Eichinger S. 6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII. Ann Hematol. 2008.
51. Berger M, Mattheisen M, Kulle B, Schmidt H, Oldenburg J, Bickeboller H, Walter U, Lindner TH, Strauch K, Schambeck CM. High factor VIII levels in venous thromboembolism show linkage to imprinted loci on chromosomes 5 and 11. Blood. 2005;105:638-644.
52. Rosendaal FR. High levels of factor VIII and venous thrombosis. Thromb Haemost. 2000;83:1-2.
53. Vormittag R, Bencur P, Ay C, Tengler T, Vukovich T, Quehenberger P, Mannhalter C, Pabinger I. Low-density lipoprotein receptor-related protein 1 polymorphism 663 C>T affects clotting factor VIII activity and increases the risk of venous thromboembolism. J Thromb Haemost. 2007;5:497-502.
54. van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol. 2008;142:889-903.
55. Hemker HC, Al Dieri R, De Smedt E, Beguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost. 2006;96:553-561.
56. Tappenden KA, Gallimore MJ, Evans G, Mackie IJ, Jones DW. Thrombin generation: a comparison of assays using platelet-poor and -rich plasma and whole blood samples from healthy controls and patients with a history of venous thromboembolism. Br J Haematol. 2007;139:106-112.
57. van Hylckama Vlieg A, Christiansen SC, Luddington R, Cannegieter SC, Rosendaal FR, Baglin TP. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol. 2007;138:769-774.
58. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA. 2006;296:397-402.
59. Tripodi A, Legnani C, Chantarangkul V, Cosrni B, Palareti G, Mannucci PM. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost. 2008;6:1327-1333.
60. Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost. 2008;6:1720-1725.
61. Eichinger S, Hron G, Kollars M, Kyrle PA. Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. Clin Chem. 2008;54:2042-2048.